PMID- 27497482
OWN - NLM
STAT- MEDLINE
DCOM- 20180126
LR  - 20180131
IS  - 1875-8908 (Electronic)
IS  - 1387-2877 (Linking)
VI  - 54
IP  - 2
DP  - 2016 Sep 6
TI  - Yokukansan in the Treatment of Behavioral and Psychological Symptoms of Dementia: 
      An Updated Meta-Analysis of Randomized Controlled Trials.
PG  - 635-43
LID - 10.3233/JAD-160418 [doi]
AB  - BACKGROUND: Previous clinical studies found that yokukansan has a therapeutic 
      effect on behavioral and psychological symptoms of dementia (BPSD) in dementia 
      patients. OBJECTIVE: To perform an updated meta-analysis of randomized controlled 
      trials (RCTs) testing yokukansan for patients with BPSD. METHODS: Primary 
      efficacy and safety endpoints were BPSD total scores and all-cause 
      discontinuation, respectively. Secondary outcomes were BPSD subscales, cognitive 
      function scores [Mini-mental state examination (MMSE)], activities of daily 
      living (ADL) scores, discontinuation due to adverse events (AEs), and incidences 
      of AEs. RESULTS: Five RCTs with 381 patients with BPSD were included. Compared 
      with controls [placebo+usual care (UC)], yokukansan significantly decreased BPSD 
      total scores [standardized mean difference (SMD) = -0.32, 95% confidence interval 
      (CI) = -0.53 to -0.11, p = 0.003, I2 = 0%, N = 5 studies, n = 361]. Yokukansan 
      was more efficacious in reducing BPSD subscale scores (delusions: SMD = -0.51, 
      95% CI = -0.98 to -0.04, hallucinations: SMD = -0.54, 95% CI = -0.96 to -0.12, 
      agitation/aggression: SMD = -0.37, 95% CI = -0.60 to -0.15) than placebo+UC. 
      However, yokukansan was not superior to placebo+UC for BPSD total as well as any 
      subscales scores only in Alzheimer's disease patients. Compared with UC, 
      yokukansan treatment improved ADL scores (SMD = -0.32, 95% CI = -0.62 to -0.01). 
      MMSE scores did not differ between the yokukansan and placebo+UC treatment 
      groups. No significant differences were found in all-cause discontinuation, 
      discontinuation due to AEs, and incidences of AEs between yokukansan and 
      placebo+UC treatments. CONCLUSIONS: Our results suggest that yokukansan is 
      beneficial for the treatment of patients with BPSD and is well-tolerated; it was 
      not beneficial for BPSD total and any subscale scores only in Alzheimer's disease 
      patients.
FAU - Matsunaga, Shinji
AU  - Matsunaga S
FAU - Kishi, Taro
AU  - Kishi T
FAU - Iwata, Nakao
AU  - Iwata N
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - Netherlands
TA  - J Alzheimers Dis
JT  - Journal of Alzheimer's disease : JAD
JID - 9814863
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Yi-Gan San)
SB  - IM
MH  - Dementia/diagnosis/*drug therapy/*psychology
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Humans
MH  - *Neuropsychological Tests
MH  - Randomized Controlled Trials as Topic/*methods
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - behavioral and psychological symptoms of dementia
OT  - dementia
OT  - meta-analysis
OT  - yokukansan
EDAT- 2016/08/09 06:00
MHDA- 2018/01/27 06:00
CRDT- 2016/08/07 06:00
PHST- 2016/08/07 06:00 [entrez]
PHST- 2016/08/09 06:00 [pubmed]
PHST- 2018/01/27 06:00 [medline]
AID - JAD160418 [pii]
AID - 10.3233/JAD-160418 [doi]
PST - ppublish
SO  - J Alzheimers Dis. 2016 Sep 6;54(2):635-43. doi: 10.3233/JAD-160418.